regardless of positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial difficulty from managed care entities. These insurers are frequently building limitations to reimbursement, including high price requirements and approval processes that limit consumer access. Indust